Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)

NCT02258542 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02258542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02258542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
November 19, 2014
Completion date
July 2, 2018
Enrollment
2,133 (actual)
Sites
429

Conditions

As the registry lists them; a condition with its own page is linked.

asthma